<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018939</url>
  </required_header>
  <id_info>
    <org_study_id>DORIPENEM IN CVVH, MARS AND HD</org_study_id>
    <nct_id>NCT02018939</nct_id>
  </id_info>
  <brief_title>Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.</brief_title>
  <official_title>Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is conducted to investigate the pharmacokinetics of Doripenem during CVVHDF
      (Continuous venovenous hemodiafiltration), MARS (Molecular Adsorbent Recirculating System)
      and intermittent hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of organ replacement therapy on area under curve of doripenem serum concentration</measure>
    <time_frame>day 15</time_frame>
    <description>Pharmacokinetic samples are drawn from each patient during the trial. Analysis by HPLC will be conducted after the end of the trial.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Infections During Organ Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetic profiling in Hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacokinetic profiling in CVVH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacokinetic profiling in MARS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic profiling</intervention_name>
    <description>Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.</description>
    <arm_group_label>Pharmacokinetic profiling in Hemodialysis</arm_group_label>
    <arm_group_label>Pharmacokinetic profiling in CVVH</arm_group_label>
    <arm_group_label>Pharmacokinetic profiling in MARS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Suspected or proven bacterial infection requiring parenteral antibiotic therapy.

          -  Organ replacement therapy (MARS, CVVHDF or HD)

        Exclusion Criteria:

          -  Known hypersensitivity to doripenem or other carbapenems, or severe hypersensitivity
             (anaphylactic reaction) to beta-lactam antibacterial agents.

          -  An expected survival of less than two days.

          -  Known pregnancy

          -  Coadministration of valproic acid or probenecid, which cannot be discontinued for the
             duration of the study

          -  Doripenem as monotherapy for resistent species or fungal infections.

          -  Other reasons opposing the study participation on the discretion of the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Florian Thalhammer</investigator_full_name>
    <investigator_title>a.o.Univ.-Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics, doripenem, renal replacement therapy, MARS, organ replacement therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

